Navigation Links
Antisoma plc (UK) - Second lung cancer trial adds to positive data,on AS1404

Rebecca Skye Dietrich Buchanan Communications +44 (0)20 7466 5000

Brian Korb/Seth Lewis The Trout Group +1 646 378 2900

Antisoma disclaimer Certain matters discussed in this statement are forward looking statements that are subject to a number of risks and uncertainties that could cause actual results to differ materially from results, performance or achievements expressed or implied by such statements. These risks and uncertainties may be associated with product discovery and development, including statements regarding the company's clinical development programmes, the expected timing of clinical trials and regulatory filings. Such statements are based on management's current expectations, but actual results may differ materially.

Details of the second lung cancer study This trial was conducted as an open-label extension to the first, randomised study of AS1404 in lung cancer. As in the randomised study, patients were receiving first-line chemotherapy treatment for stage IIIb or IV non-small cell lung cancer. All patients received 1800 mg/m2 AS1404 in combination with carboplatin and paclitaxel. The trial was conducted at hospitals in Germany and New Zealand.

Background on AS1404 AS1404 (DMXAA) is a small-molecule vascular disrupting agent which targets the blood vessels that nourish tumours. The drug was discovered by Professors Bruce Baguley and William Denny and their teams at the Auckland Cancer Society Research Centre, University of Auckland, New Zealand. It was in-licensed by Antisoma from Cancer Research Ventures Limited (now Cancer Research Technology), the development and commercialisation company of the Cancer Research Campaign (now Cancer Research UK), in August 2001. CRUK had supported two phase I studies in the UK and New Zealand.

Background on Antisoma Based in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. Antisoma fills its development pipeline by acqui
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Data supporting three Antisoma programmes presented at AACR
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
5. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
8. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
9. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
10. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
11. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Antisoma plc Second lung cancer trial adds positive data
(Date:8/20/2014)... -- Research and Markets  has announced the addition of ... their offering. Global Market Report of Pralmorelin ... and regionally ( Europe , Asia ... Latin America etc.). It captures Pralmorelin market trends, ... on three primary areas; manufacture methods & technology development, market ...
(Date:8/20/2014)... Ariz. , Aug. 20, 2014   ... the  Roche  Group, today announced that its VENTANA ... CE marked in the European Union for routine ... The system, consisting of VENTANA Virtuoso software coupled ... VENTANA iScan HT slide scanner, provides automated digital ...
(Date:8/20/2014)... PHOENIX , Aug. 20, 2014 /PRNewswire-USNewswire/ ... next-generation sequencing and proteomic diagnostics and biomarker driven ... collaboration with TESARO, Inc.  Paradigm will use its ... from clinical trials to better predict which patients ... may lead to more successful clinical trial outcomes ...
Breaking Medicine Technology:Global Market Report of Pralmorelin 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc. 2
(Date:8/21/2014)... According to new market research ... Food & Beverage, Personal care & Pharmaceutical) & ... Electronics, Textile) & Geography - Global Trends & ... polylactic acid markets and segments with analyses and ... on their sub-segments, in terms of value and ...
(Date:8/21/2014)... San Luis Obispo, CA (PRWEB) August 21, 2014 ... July/August edition of Current Pedorthics, a bi-monthly publication of the ... the field of pedorthics. , Bunion Bootie ... as an alternative solution for bunion sufferers and their pain. ... be worn in nearly any shoe to eliminate the friction ...
(Date:8/21/2014)... WA (PRWEB) August 21, 2014 While ... Grant, found it hard to stay focused on his ... and mosquitoes. The constant whine, slapping and continual need ... researching innovative methods to stay protected from insects while ... successful career in the Financial Services/Investment Banking Industry, decided ...
(Date:8/21/2014)... 2014 Atlantic Information Services, Inc. (AIS) ... News and The AIS Report on Blue Cross & ... Blue Shield Association or its member companies) — is ... in AIS’s Management Insight Series. Bundled Payment Models: ... two insurers — Horizon Healthcare Services, Inc. and Arkansas ...
(Date:8/21/2014)... 2014 AttorneyOne.com, a recognized authority on ... information from the FDA on Dianeal Low Calcium ... announced on August 15, that two lots of Dianeal ... 5000mL (Ambu-Flex II), by Baxter International Inc., are ... , The reason for the recall is the ...
Breaking Medicine News(10 mins):Health News:Lactic Acid Market Worth $3,577.5 Million & Polylactic Acid Market Worth $4,840.1 Million by 2019 – New Report 2Health News:Lactic Acid Market Worth $3,577.5 Million & Polylactic Acid Market Worth $4,840.1 Million by 2019 – New Report 3Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 2Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 3Health News:Financial VP Fights Pesky Bugs with Launch of Biteback Sports Insect Shield® Golf Apparel 2Health News:New AIS Report Highlights Two Case Studies of Bundled Payment Models 2Health News:Dianeal Low Calcium (2.5mEq/L) Peritoneal Dialysis Solution with 2.5% Dextrose 5000mL (Ambu-Flex II) Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2
... humans are genetically more suited to being vegetarians than meat-eaters ... conference by more then 300 leading scientists from New Zealand ... finding a cure for cancer is also under discussion at ... Convener of the conference says the finding that a human ...
... drawer, the time-honored lessons of helping organize one’s clothes learned ... to encode such categories as socks, shirts, or any other ... research from Harvard Medical School (HMS) investigators has identified an ... report in the advanced online Nature that they have identified ...
... Palmerston North high school, 500 will undergo testing this week ... students will be tested in the coming weeks. ... and laboratory tests have now confirmed the boy has tuberculosis. ... and parents revealed exposure to the infecting bacteria. The remaining ...
... skin lightening products are available over the counter but the ... over the counter skin lighteners that contain hydroquinone because studies ... causing. ,Dermatologist, Dr. Mathew Avram, of Massachusetts General Hospital ... here. I think they haven't seen the data to show ...
... that studies that were being conducted towards pest control ... ,Researchers from the University of California, have stated ... been identified by researchers who were initially looking for ... for people suffering from arthritis and other inflammatory diseases. ...
... present in almost every medicine cabinet, may help in easing ... Clinic.// ,Aspirin is known to help in the ... of cancer along with headaches. The researchers say that now ... to have been connected with enlarged prostates. ,It ...
Cached Medicine News:Health News:Brain's Filing System Uncovered 2Health News:Brain's Filing System Uncovered 3Health News:Pest Control research Leads to Pain Control Discovery 2Health News:Pest Control research Leads to Pain Control Discovery 3
... The BiPAP Pro with Bi-Flex bi-level system, ... that the BiPAP Pro takes to change ... Digital Auto-Trak Sensitivity™ which automatically triggers the ... pressures based on the patients breathing rhythm. ...
... Electrophoresis System (PGGE) is designed to ... density lipoproteins (LDL) and high density ... using nondenaturing pore gradient gel electrophoresis. ... short DNA sequencing runs. Temperature control ...
This control is intended for monitoring cell counts in patient cerebrospinal fluid samples, performed manually using a hemocytometer. Spinalscopics is fortified to target levels with purified chemica...
... Suitable for use with Leica ... bilirubinometers (pediatric) and all automated ... including Aeroset, AU Series, Cobas, ... These controls contain purified bilirubin ...
Medicine Products: